BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9496907)

  • 21. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH; Jardines LA; Chang H; Ruggeri B
    J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
    Sastre-Garau X; Genin P; Rousseau A; Al Ghuzlan A; Nicolas A; Fréneaux P; Rosty C; Sigal-Zafrani B; Couturier J; Thiery JP; Magdelénat H; Vincent-Salomon A
    Histopathology; 2004 Aug; 45(2):142-7. PubMed ID: 15279632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast.
    Tanaka T; Kimura M; Matsunaga K; Fukada D; Mori H; Okano Y
    Cancer Res; 1999 May; 59(9):2041-4. PubMed ID: 10232583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
    Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
    Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
    Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
    Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
    Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.
    Okita S; Tsutsumi M; Onji M; Konishi Y
    Mol Carcinog; 1995 Aug; 13(4):266-71. PubMed ID: 7646765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
    Saint-Ruf C; Malfoy B; Scholl S; Zafrani B; Dutrillaux B
    Oncogene; 1991 Mar; 6(3):403-6. PubMed ID: 1826346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.
    Trevino JG; Summy JM; Gray MJ; Nilsson MB; Lesslie DP; Baker CH; Gallick GE
    Cancer Res; 2005 Aug; 65(16):7214-22. PubMed ID: 16103072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene.
    Wallrapp C; Müller-Pillasch F; Solinas-Toldo S; Lichter P; Friess H; Büchler M; Fink T; Adler G; Gress TM
    Cancer Res; 1997 Aug; 57(15):3135-9. PubMed ID: 9242439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Akt2 Inhibits anoikis and apoptosis induced by myogenic differentiation.
    Fujio Y; Mitsuuchi Y; Testa JR; Walsh K
    Cell Death Differ; 2001 Dec; 8(12):1207-12. PubMed ID: 11753568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
    Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
    Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes.
    Holzmann K; Kohlhammer H; Schwaenen C; Wessendorf S; Kestler HA; Schwoerer A; Rau B; Radlwimmer B; Döhner H; Lichter P; Gress T; Bentz M
    Cancer Res; 2004 Jul; 64(13):4428-33. PubMed ID: 15231651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma.
    Cavallari I; Silic-Benussi M; Rende F; Martines A; Fogar P; Basso D; Vella MD; Pedrazzoli S; Herman JG; Chieco-Bianchi L; Esposito G; Ciminale V; D'Agostino DM
    Genes Chromosomes Cancer; 2009 May; 48(5):383-96. PubMed ID: 19170121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival.
    Sessa F; Bonato M; Bisoni D; Ranzani GN; Capella C
    Eur J Histochem; 1998; 42 Spec No():67-76. PubMed ID: 10076772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    van de Vijver MJ; Peterse JL; Mooi WJ; Wisman P; Lomans J; Dalesio O; Nusse R
    N Engl J Med; 1988 Nov; 319(19):1239-45. PubMed ID: 2903446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.